scispace - formally typeset
M

Michel Alary

Researcher at Laval University

Publications -  236
Citations -  5290

Michel Alary is an academic researcher from Laval University. The author has contributed to research in topics: Population & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 37, co-authored 236 publications receiving 4899 citations. Previous affiliations of Michel Alary include Université du Québec.

Papers
More filters
Journal ArticleDOI

Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis

TL;DR: Investigating whether incarceration history elevates HIV or HCV acquisition risk among PWID supports the need for developing novel interventions to minimise the risk of HCV and HIV acquisition, including addressing structural risks associated with drug laws and excessive incarceration of PWID.
Journal ArticleDOI

High hepatitis C virus prevalence and incidence among Canadian intravenous drug users

TL;DR: The epidemiology of hepatitis C virus (HCV) infection among injection drug users (IDUs) in Eastern Central Canada and independent predictors of seroconversion were age, injecting for a year or less, injecting with a syringe previously used by someone else, injecting most often cocaine, engaging in prostitution, and being recruited in a major urban centre.
Journal ArticleDOI

Etiology of urethral discharge in West Africa: the role of Mycoplasma genitalium and Trichomonas vaginalis

TL;DR: The frequent occurrence of multiple infections with any combination of four pathogens strongly supports the syndromic approach and the optimal use of metronidazole in flowcharts for the Syndromic management of urethral discharge needs to be explored in therapeutic trials.
Journal ArticleDOI

PrEP implementation research in Africa: what is new?

TL;DR: Throughout the continent, individuals in sero‐discordant relationships, and members of key populations (sex workers, men who have sex with men (MSM), transgender women and injection drug users) are likely to benefit from the availability of PrEP.